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patients progressing on vemurafenib
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Peta Hughesa, Komel Khabrab, Martin Gorea and James Larkina
The BRAF inhibitor vemurafenib is an effective drug in
patients with BRAF mutant metastatic melanoma, but
resistance occurs after a median of 6 months. The anti-
CTLA4-antibody, ipilimumab, is a standard first-line and
second-line treatment option in Europe, with a median time
to response of 2–3 months, but some patients show rapid
clinical deterioration before that. The aim of this analysis
was to identify prognostic markers for survival after failure
of vemurafenib treatment to identify patients who have a
sufficient life expectancy to respond to new immunotherapy
treatments. We retrospectively analysed 101 consecutive
unselected patients treated with vemurafenib for metastatic
melanoma at a single institution. The association between
clinical parameters and death within 3 months after
cessation of vemurafenib (n= 69) was assessed by binary
logistic and Cox regression. Of the patients, 45% died within
3 months of progression on vemurafenib. Elevated baseline
serum lactate dehydrogenase, absence of normalization of
serum lactate dehydrogenase on vemurafenib therapy,
performance status of at least 2 at progression and time
from primary tumour to metastatic disease less than
5 years were identified as poor prognostic markers. In an
exploratory tumour growth kinetics analysis (n=16), we
found that following cessation of vemurafenib,
approximately a third each showed a stable, decelerated or
accelerated rate of tumour growth. Patients with these poor
prognostic markers are unlikely to have sufficient life
expectancy to complete ipilimumab treatment after failure
with vemurafenib. Consideration needs to be given to the
elective use of immunotherapy before patients become
resistant to vemurafenib. This requires prospective
randomized evaluation. Our tumour growth kinetics analysis
requires confirmation; however, it may suggest that
intermittent vemurafenib treatment should be investigated
in clinical trials. Melanoma Res 26:138–144 Copyright ©
2016 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Malignant melanoma is currently the ninth most common
cancer in Europe, and incidence rates have been
increasing worldwide (http://www.cancer.org; http://www.
cancerresearchuk.org). Until recently, therapeutic options
for patients with metastatic melanoma were limited, and
5-year survival rates of 10–20% largely reflected the
natural history of the disease.
Major treatment advances have been made over the past
4 years, with the approval of five agents by the European
Medical Association for the treatment of metastatic
melanoma: in 2011, ipilimumab [1] – an anti-CTLA4
antibody – and vemurafenib [2] – a selective BRAF
inhibitor – were approved. More recently, the BRAF
inhibitor, dabrafenib, and the MEK inhibitor, trametinib,
were also approved [3,4]. In addition, the new anti-
PDL1-agent, pembrolizumab, and the anti-PD1-agent,
nivolumab, have been approved.
Approximately 40% of melanomas harbour activating
mutations in the protein kinase BRAF (Catalogue of
Somatic Mutations in Cancer database). In metastatic
melanoma patients harbouring a BRAF V600 mutation,
treatment with vemurafenib results in improved
progression-free survival (PFS) and overall survival (OS)
compared with chemotherapy with dacarbazine, espe-
cially in patients with large tumour burden [5–7]. The
most important limitation of BRAF-targeted therapy is
the relatively short duration of the antitumour effect: the
median PFS is 6–7 months and resistance is almost
universal.
In contrast, immunotherapy has limited response rates of
10–20% with ipilimumab and 30% with pembrolizumab
or nivolumab in metastatic melanoma; however, long-
term control can be achieved in some patients indepen-
dent of the BRAF mutation status, and better responses
are often seen in patients with lower tumour burden [1,
8–10]. Until late 2013, ipilimumab was licensed only in
Europe as a second or subsequent line of treatment.
Therefore, until recently, in Europe, outside of the
context of clinical trials, standard treatment for BRAF
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mutant melanoma consisted of vemurafenib followed by
ipilimumab. Immunotherapy typically requires at least
8–12 weeks for a response to be seen, and consequently,
patients embarking on this therapy need to have a life
expectancy of at least 3 months. Clinical experience
suggests that patients with rapidly growing disease after
progression on vemurafenib do not benefit from immuno-
therapy [9]. To date, apart from adequate performance
status (PS), prognostic markers of potential benefit have
not been defined. However, we have shown that a serum
lactate dehydrogenase (LDH) level greater than two
times the upper limit of normal is a negative prognostic
marker for long-term benefit from ipilimumab [11].
We carried out a retrospective analysis to identify prog-
nostic parameters and which patients have a sufficient
life expectancy to respond to new immunotherapy
treatments following progression on vemurafenib. We
also carried out an exploratory comparative analysis of
tumour growth kinetics during progression on vemur-
afenib and after the cessation of the drug but before the
instigation of subsequent therapy.
Methods
Patients
In this retrospective case series, we analysed all patients
who had been treated with and progressed on vemur-
afenib as a single-agent therapy for metastatic melanoma
harbouring a BRAF V600 mutation at a single institution
(Royal Marsden Hospital, London, UK) from March 2010
to May 2013. Patients were treated with vemurafenib
within the BRAF inhibitor in Melanoma (BRIM-3) study
(NCT01006980, enrolment period March 2010 until
December 2010), the vemurafenib safety study
(NCT01307397, enrolment period March 2011 until
January 2013) as well as off trial after approval from the
European Medicines Agency in December 2011.
Exclusion criteria were treatment with vemurafenib for
malignancies other than melanoma, cessation of vemur-
afenib for reasons other than progressive disease, such as
toxicity, and lack of radiological confirmation of pro-
gressive disease, for example, death before radiological
confirmation of progressive disease.
The primary aim of the analysis was the identification of
the proportion of patients with early death (ED; defined
as death ≤ 90 days after progression on vemurafenib) and
their clinical characteristics compared with patients with
late death (LD; defined as death > 90 days after pro-
gression on vemurafenib). Any patient who was alive but
had not yet reached at least 90 days of follow-up after
cessation of treatment were not included in the ED/LD
analysis. We also described the PFS, OS and prognostic
markers for OS for all patients analysed.
In an exploratory analysis, we measured tumour growth
rates (TGRs) while patients were progressing on
vemurafenib compared with those after stopping
vemurafenib but before subsequent therapy or best
supportive care was instigated. Only patients who had
not/not yet started further treatment after stopping
vemurafenib were included in the analysis. TGRs were
measured as percentage per week and assessed using a
modified form of Response Evaluation Criteria In Solid
Tumours (RECIST 1.1) by two independent observers:
TGRs were calculated as the change in the sum diam-
eters of the target lesions and up to five new lesions
between the most recent computed tomography (CT)
scan before and at the time of stopping vemurafenib
(TGR1) and between the CT scan at cessation of
vemurafenib and the subsequent CT scan after stopping
vemurafenib (TGR2). An increase of at least 5% per
week between TGR1 and TGR2 (ΔTGR) was con-
sidered as accelerated, − 5%>ΔTGR< 5% per week was
considered stable and ΔTGR of up to − 5% per week was
considered as decelerated tumour growth. These cutoff
values correspond to 20% tumour growth as per RECIST
1.1 – that is, progressive disease over a 4-week interval.
Statistical methods
All statistical analyses were carried out using the SPSS
software, version 21.0 (SPSS Inc., Chicago, Illinois, USA).
Univariate binary logistic regression analyses were used
to test for any variable associated with ED. Univariate
Cox regression analyses were used to test for any variable
associated with OS. P-values less than 0.05 were con-
sidered significant. Variables with P less than 0.05 were
entered into a multivariate model in a forward stepwise
manner. PFS, postprogression survival (PPS) and OS
analyses were carried out using the Kaplan–Meier
method. PFS was defined as the time from the start of
vemurafenib to progression. PPS was defined as the time
from cessation of vemurafenib until death. OS was
defined as the time from the start of vemurafenib until
death. Patients alive at time of evaluation were censored
at the last follow-up (cutoff 30 September 2013). Patients
lost to follow-up were censored at the last follow-up.
Results
Clinical characteristics of patients with progression on
vemurafenib
Between March 2010 and May 2013, 101 patients were
treated with vemurafenib as a single agent for metastatic
melanoma. At the time of evaluation, 69 (68%) had
stopped vemurafenib for radiologically confirmed pro-
gressive disease (Table 1). This formed the case series
population.
The patients were treated outside trials, within the
vemurafenib safety study and within the BRIM-3 study
(20, 70 and 10%, respectively). An overview of the clin-
ical characteristics of all patients who progressed on
vemurafenib is given in Table 2. The majority of the
patients were treatment-naive before starting vemur-
afenib (70%): 21 (30%) patients had undergone at least
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one systemic treatment before vemurafenib, including
two patients having being treated with ipilimumab.
Before commencing vemurafenib, 70% of the patients
had an elevated LDH, 16% had an Eastern Cooperative
Oncology Group PS of at least 2 and 20% had central
nervous system (CNS) disease; 26% of the patients had
two of these three characteristics, and one patient had
all three.
The median follow-up from starting vemurafenib was
20.4 months [95% confidence interval (CI): 15.4–25.4].
The median PFS was 4.1 months (95% CI: 2.7–5.6;
Table 3). The median PPS was 3.2 months (95% CI
2.2–4.2). In nine of 69 patients the date of death was
unknown because of loss to follow-up.
Post vemurafenib therapy
After progression on vemurafenib, 28 patients (41%)
received further active therapy (Table 2); the same pro-
portion of patients received best supportive care because
of clinical deterioration, according to the his/her pref-
erence and/or as ipilimumab was not yet available at the
time of progression. Thirteen patients (19%) were lost to
follow-up. Out of the 56 patients in whom post-
vemurafenib management is known, 21 (38%) received
subsequent treatment with ipilimumab and seven (12%)
received other systemic therapies, but only eight of these
patients were able to complete the full course of four
doses of ipilimumab. This represents 14% of the total
population in whom follow-up management is known
and 38% of those who commenced ipilimumab. Seven
died before completion of ipilimumab therapy, and three
patients discontinued ipilimumab for progression on
treatment (Table 2). All patients who were treated with
ipilimumab had a PS of up to 1 before starting this
therapy. All patients who completed four doses of ipili-
mumab had a normal baseline LDH before starting
vemurafenib or an elevated baseline LDH that normal-
ized while on treatment with vemurafenib. One of those
eight patients (12%) responded to ipilimumab, whereas
the others showed progressive disease.
Prognostic impact of clinical features
We explored the prognostic significance of clinical para-
meters in all patients who progressed on vemurafenib:
age, sex, CNS involvement at baseline, progression
within the CNS, elevated LDH at baseline and at pro-
gression, absence of normalization of LDH on vemur-
afenib, PS at baseline and progression, time between
diagnosis of the primary tumour and development of
Table 1 Overview of patients on vemurafenib
n (% of total)
Total patients on vemurafenib 101
Cessation of vemurafenib at the time of evaluation 87 (86)
Cessation of vemurafenib for progressive disease 69 (68)
Cessation of vemurafenib for toxicities 6 (6)
PD not confirmed radiologically before cessation of
vemurafenib
12 (12)
No cessation of vemurafenib at time of evaluation 14 (14)
PD, progressive disease.
Table 2 Clinical characteristics of all patients with progression on vemurafenib, those with early death (death ≤3 months after progression
on vemurafenib) and those with late death (death >3 months after progression on vemurafenib)
All Early death Late death
Total (n) 69 31 30
Baseline
Age (range) (years) 52.7 (18–77) 52.4 (18–77) 52.3 (22–74)
Male [n (%)] 40 (58) 19 (61) 15 (50)
Female [n (%)] 29 (42) 12 (39) 15 (50)
Time from primary tumour to metastatic disease <5 years [n (%)] 53 (77) 29 (94)* 20 (67)
Systemic treatment before vemurafenib [n (%)] 21 (30) 9 (29) 10 (33)
Stage M1c [n (%)] 55 (80) 28 (90) 21 (70)
Normal LDH [n (%)] 21 (30) 4 (13) 14 (47)
Elevated LDH [n (%)] 48 (70) 27 (87)* 16 (53)
PS 0/1 [n (%)] 58 (84) 23 (74) 27 (90)
PS≥2 [n (%)] 11 (16) 8 (26) 3 (10)
CNS involvement [n (%)] 14 (20) 8 (26) 5 (17)
On treatment with vemurafenib
LDH, normalized [n (%)] 38/48 (79) 19/27 (70) 16/16 (100)
LDH, not normalized [n (%)] 10/48 (21) 8/27 (30) –
Elevated LDH at progression [n (%)] 34 (49) 19 (61) 12 (40)
PS≥2 at progression [n (%)] 26 (38) 18 (58)* 5 (17)
Postprogression treatment [n (%)] 28 (41) 7 (23)** 20 (67)
Ipilimumab 21 (30) 5 (16) 14 (47)
Completed ipilimumab 8/21 (38) – 8/14 (57)
Discontinued ipilimumab (PD/death) 10/21 (48) 5/5 (100) 5/14 (36)
Discontinued ipilimumab (toxicities) 2/21 (10) – 1/14 (7)
Lost to follow-up 1/21 (5) – –
CNS, central nervous system; LDH, lactate dehydrogenase; n, number of patients; PD, progressive disease; PS, performance status.
P-values indicate correlation between clinical variables and early death.
*P<0.05.
**P<0.001.
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metastatic disease and stage of metastatic disease at the
start of vemurafenib.
In multivariate analysis, PS of at least 2 at progression and
time between diagnosis of the primary tumour and
development of metastatic disease less than 5 years were
associated with poor OS [hazard ratio (HR) 3.4 (95% CI:
1.7–7.0), P= 0.001 and HR 6.4 (95% CI: 2.5–16.4),
P< 0.001, respectively; Table 4].
Patients with elevated baseline LDH levels showed a
tendency towards poorer OS compared with those with
normal LDH [HR 1.8 (95% CI: 1.0–3.3), P= 0.06].
However, the absence of normalization of LDH was an
independent marker for poor OS [HR 8.6 (95% CI:
2.8–26.6), P< 0.001; Table 4]. No difference in outcome
was seen between patients with normal baseline LDH
levels and those with elevated baseline LDH levels that
normalized (Fig. 1). Approximately two-thirds of the
patients (60%) with LDH normalization showed a second
rise in LDH before subsequent progressive disease. In
87% of patients, progression occurred within the next
2 months, with a median time to progression of 29 days
(range 0–168) from secondary abnormal LDH.
Prognostic markers for early death
Thirty-one of 69 patients (45%) died within 90 days
(ED), whereas 30 patients (43%) survived longer than
90 days (LD; Table 2). Eight patients had not yet
reached 90 days since stopping vemurafenib at the time
of the analysis and were excluded from the analysis.
There were no differences between patients with ED/
Table 3 Clinical and radiological outcome of all patients with progression on vemurafenib and of patients with early death (death ≤ 3 months
after progression on vemurafenib) and late death (death > 3 months after progression on vemurafenib)
All Early death Late death
Total (n) 69 31 30
Clinical outcome
1-year OS rate (95% CI) (%) 27 (15–39) 3 (0–9) 47 (29–66)
Median OS (95% CI) (months ) 8.5 (6.7–10.2) 4.4 (3.7–5.2) 11.7 (10.2–13.1)
Median PFS (95% CI) (months) 4.1 (2.7–5.6) 3.7 (3.5–3.9) 6.4 (5.2–7.7)
Median PPS (95% CI) (months) 3.2 (2.2–4.2) 1.3 (0.6–2.0) 5.1 (3.9–6.3)
Radiological outcome
Clinical benefit (CR, PR, SD) [n (%)] 60 (87) 26 (84) 29 (97)
Primary refractory disease [n (%)] 9 (13) 5 (16) 1 (3)
Best response after cycle 2 [n (%)] 54 (78) 29 (93) 20 (60)
Median time from BL to BR (95% CI) (months) 1.8 (1.2–7.1) 1.7 (1.2–7.1) 1.8 (1.2–5.5)
Median time from BR to PD (95% CI) (months) 2.0 (0.1–12.9) 1.9 (0.1–12.9) 3.7 (0.2–11.7)
BL, baseline; BR, best response; CI, confidence interval CR, complete remission; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PPS,
postprogression survival; PR, partial response; SD, stable disease.
Table 4 Prognostic factors for early death and overall survival:
multivariate analysis
OR 95% CI P-value
Prognostic factors for early death
Time from primary tumour to metastatic
disease<5 years
12.82 1.93–83.33 0.008
PS at progression ≥2 6.86 1.60–29.42 0.010
Elevated LDH at baseline 5.48 1.31–23.01 0.020
HR 95% CI P-value
Prognostic factors for overall survival
Time from primary tumour to metastatic
disease <5 years
6.41 2.49–16.39 <0.001
Normal LDH at baseline (reference) 1
LDH, normalized 1.17 0.56–2.41 0.680
LDH, not normalized 8.62 2.80–26.61 <0.001
Overall <0.001
PS at progression ≥2 3.45 1.70–7.02 0.001
Elevated LDH at baseline, LDH, normalized and not normalized, PS≥2 at pro-
gression, time from primary tumour to metastatic disease≥5 years were all
entered into a multivariate model in a forward conditional selection manner.
CI, confidence interval; HR, hazard ratio; LDH, lactate dehydrogenase; PS, per-
formance status.
Fig. 1
100
80
60
40
20
0
O
ve
ra
ll 
su
rv
iv
al
 (%
)
0 5 10
Time in months from starting vemurafenib
15 20 25
LDH normal (n= 21) 
HR 6.88
(95% Cl: 2.87 − 16.51)
P< 0.001 
HR 10.51
(95% Cl: 3.96 − 27.85)
P< 0.001 
LDH normalized (n= 38) 
LDH not normalized (n= 10) 
Overall survival curves of patients with normal baseline LDH and
elevated baseline LDH with normalization and without normalization.
Overall survival was defined as time from start of vemurafenib until
death. Vertical lines indicate that the patients’ data were censored. The
median follow-up period on vemurafenib was 20.4 months. No
significant difference in overall survival was observed between patients
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dehydrogenase.
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LD in relation to age, sex, stage of metastatic disease,
prior treatment or PS at baseline.
Elevated prevemurafenib baseline LDH [odds ratio
(OR) 5.5 (95% CI: 1.3–23.0), P= 0.02], PS of at least 2 at
the time of progression [OR 6.9 (95% CI: 1.6–29.4),
P= 0.01] and time between diagnosis of the primary
tumour and development of metastatic disease less than
5 years [OR 12.8 (95% CI: 1.9–83.3), P= 0.008] were
correlated with ED (Table 4). All patients who had ele-
vated baseline LDH before vemurafenib treatment and
never showed normalization of their LDH (n= 8)
belonged to the ED group.
Influence of stopping of vemurafenib on tumour growth
We analysed the preprogression and postprogression
tumour growth kinetics in 16 out of the 69 patients (three
ED patients, 12 LD patients and one patient who had
not yet reached 90 days of follow-up) in whom post-
progression CT scanning was performed following the
cessation of vemurafenib treatment and before the
instigation of further active therapy or best supportive
care. The reasons for the lack of evaluable CT were as
follows: immediate initiation of a further treatment
(n= 15), palliative care without a further scan (n= 27),
external CT (n= 7), partial CT (n= 3) and no subsequent
scan yet at the time of evaluation (n= 1).
The median time between CT scans before and at the
time of stopping vemurafenib was 8 weeks (range 4–12
weeks). The median time between CT scans at and after
stopping vemurafenib was 5 weeks (range 4–14 weeks).
The median TGRs before and after progression on
vemurafenib were + 6.1% per week (range − 3.5 to
+ 156.5%) and + 14.7% per week (range + 0.7 to
+ 45.2%), respectively – that is, a 2.4-fold median
increase in growth rate. Seven out of 16 patients (44%)
showed an acceleration of tumour growth, with ΔTGR of
at least 5% per week after stopping vemurafenib
(Fig. 2a), whereas in five patients (31%), the tumour
growth was stable (− 5%>ΔTGR< 5% per week;
Fig. 2b), and in four patients (25%), a deceleration in
tumour growth was seen (ΔTGR≤−5% per week;
Fig. 2c). The median OS for these three groups was 9.0
(range 2.0–13.0), 10.0 (range 3.0–20.0) and 11.0 (range
8.0–23.0) months, respectively. None of the patients with
decelerated TGR had received immunotherapy before
vemurafenib. Three out of 16 patients (two with decel-
erated TGR and one with accelerated TGR) received
ipilimumab after vemurafenib. One each completed the
full course of ipilimumab, but both showed subsequent
progression.
Discussion
Our data demonstrate that a significant number of
patients with progressive disease on vemurafenib do not
have sufficient life expectancy to potentially complete
subsequent treatment with ipilimumab or to even
respond to new immunotherapy, and others have made a
similar observation [12]. In this analysis, the median
survival was 3.2 months, with 45% of patients dying
within 3 months (ED) of stopping vemurafenib. An ele-
vated baseline LDH, PS of at least 2 at progression and
time between diagnosis of the primary tumour and
development of metastatic disease less than 5 years were
correlated with ED. All three parameters are well-known
prognostic factors for metastatic melanoma.
Despite our limited sample size, these data suggest that if
ipilimumab is to be administered after vemurafenib, then
serious consideration needs to be given to a vemurafenib
‘induction’ strategy. For example, patients could receive
vemurafenib until maximum response, normalization of
poor prognostic factors or for an arbitrary period such as
8–16 weeks (two to four cycles), followed by immuno-
therapy utilizing immune checkpoint inhibition. In a
recent small series, all 11 patients treated early with ipi-
limumab after two to four induction cycles of vemur-
afenib were alive at a median follow-up of 1 year,
compared with seven out of eight patients who were
reported to have died on switching to vemurafenib on
progression [13]. This strategy of elective sequential
hybrid therapy of targeted agent immunotherapy
requires prospective evaluation. A current prospective
trial investigates how BRAF/MEK inhibitor treatment
and immunotherapy treatment should be sequenced in
patients with advanced BRAF mutant melanoma
(NCT02224781).
We have found that our patients with an elevated base-
line LDH that normalized while on vemurafenib showed
a significantly better OS than patients without normal-
ization of this serum enzyme. The normalization of LDH
may also be important when we try to predict who will
benefit from postvemurafenib ipilimumab. Only eight
patients (14%) out of the 56 patients in whom post-
vemurafenib treatment is known were able to receive all
four doses of ipilimumab; normalization of LDH while on
vemurafenib was a feature of those who were able to
complete this immunotherapy. A previously reported
case series of 28 patients treated with BRAF inhibitors
followed by ipilimumab suggested clinical baseline mark-
ers such as elevated baseline LDH, PS greater than 0 and
CNS involvement to be indicators of failure of comple-
tion of second-line treatment [14]. The relationship
between normalization of LDH and the ability of
patients to receive or complete subsequent therapy is
important as it impacts how we sequence new treatments
and design elective sequential hybrid therapy.
Our exploratory study of TGR suggests that a majority of
patients will show a steady or even an accelerated pace of
disease after cessation of vemurafenib, but approximately
one-third showed a deceleration of tumour growth.
Although the accuracy of the method that we used is
limited and the number of patients with accelerated
142 Melanoma Research 2016, Vol 26 No 2
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tumour growth is likely to be underestimated in this
selective analysis as a significant number had no sub-
sequent CT scanning after stopping of vemurafenib, our
findings imply that tumour evolutionary pressure is not
always towards a more malignant phenotype. Preclinical
data have demonstrated increased tumour proliferation of
resistant tumours only in the presence of vemurafenib;
however, following drug cessation, tumour regression was
observed [15]. This finding is consistent with our tumour
kinetic analysis, which shows that following cessation of
vemurafenib, 25% of patients had a deceleration of TGR.
An obvious clinical consequence of this observation is
Fig. 2
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that intermittent dosing of targeted agents may be a
therapeutic strategy for some patients. Indeed, this
approach has been shown to delay the onset of drug
resistance in mice [15].
Rationally designed prospective clinical trials based on
observations such as those presented here are urgently
required to try and improve outcomes for patients by
maximizing the relatively limited benefit from our
existing therapies.
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